MOA Platform Heatmaps
Pick a mechanism-of-action family and see every drug against that target across all indications — “all assets against target X.” Each grid is drugs (rows) × indications (columns), with forward catalysts and per-asset detail.
19 curated families · 632 drugs mapped
IO checkpoint inhibitors
ProPD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3 antibodies and bispecifics — the most-mature IO landscape.
Antibody-drug conjugates (ADCs)
ProAntibody-drug conjugates spanning multiple tumor antigens. The dominant emerging modality across solid tumors.
T-cell engagers (CD3 bispecifics)
ProBispecific antibodies engaging T-cells via CD3 to a tumor antigen. The fastest-growing class in oncology after IO and ADCs.
GLP-1 / incretin agonists
ProGLP-1 and multi-incretin (GIP, glucagon, amylin) agonists across obesity, type 2 diabetes, MASH, and cardiometabolic — the highest-value cross-indication race in pharma.
EGFR family inhibitors
ProEGFR TKIs across generations, exon-20 selective, bispecifics, and EGFR ADCs.
CD19-targeted therapies
ProCD19-directed therapies across modalities (CAR-T, T-cell-engaging bispecifics, mAb/ADC) AND across domains — the heme-oncology workhorse (lymphoma/leukemia) now crossing into autoimmune disease (lupus, myasthenia, scleroderma, myositis), where CD19 CAR-T "resets" the B-cell compartment.
HER2 family
ProHER2 mAbs, ADCs, bispecifics, and small-molecule TKIs.
KRAS family inhibitors
ProKRAS inhibitors spanning G12C, G12D, G12V, pan-RAS, RAS(ON), KRAS vaccines, and KRAS-targeted TCR-T.
JAK / TYK2 inhibitors
ProJAK pan / JAK1 / JAK1/2 / JAK3 / TYK2 inhibitors — the oral kinase backbone across immunology, dermatology, myeloproliferative neoplasms, and (emerging) CNS.
BCMA-targeted therapies
ProBCMA-directed therapies across modalities — CAR-T, T-cell-engaging bispecifics, and ADCs — the dominant target in relapsed/refractory multiple myeloma.
CAR-T cell therapy
ProAutologous and allogeneic CAR-T cells across hematologic and solid tumor targets.
Radioligand therapies
ProPSMA / SSTR2 / FAP-targeted radioligand therapies — the fast-emerging precision-oncology modality.
PARP / DDR inhibitors
ProPARP inhibitors and broader DNA-damage-response (ATR, WEE1) inhibitors.
IL-23 axis inhibitors
ProIL-12/23 (p40) and IL-23 (p19) inhibitors — the dominant immunology class for psoriasis, IBD, and emerging.
TL1A inhibitors
ProTL1A antibodies for IBD — the most-crowded emerging mechanism in UC and CD across 6 sponsors.
Claudin 18.2 targeting
ProClaudin 18.2 mAbs, ADCs, bispecifics, and CAR-T across gastric and PDAC.
MTAP synthetic-lethal inhibitors
ProPRMT5 and MAT2A inhibitors exploiting MTAP-deletion vulnerability — selective oncology synthetic-lethal class.
S1P modulators
ProSphingosine-1-phosphate receptor modulators for UC, MS, and other indications.
mRNA neoantigen vaccines
PromRNA-encoded personalized neoantigen and shared antigen cancer vaccines.
Data: ClinicalTrials.gov · Curated target-family rosters · Updated weekly.